Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly Depreciation & Amortization (CF) of $564000.0 for Q4 2025, down 18.14% year-over-year from $689000.0 in Q4 2024, and down 3.09% quarter-over-quarter from $582000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $564000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 18.14% year-over-year to $564000.0; the TTM figure through Dec 2025 stood at $2.5 million (up 8.71% YoY), while the FY2025 annual figure was $2.5 million, up 8.67% from the prior year.
- Depreciation & Amortization (CF) declined to $564000.0 in Q4 2025 per INBX's latest filing, from $582000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $760000.0 in Q3 2024 and bottomed at $295000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $514909.1 across 3 years, with a median of $564000.0 in 2025.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 150.0% — and 2025, when it fell 23.42%.
- Inhibrx Biosciences' Depreciation & Amortization (CF) stood at $298000.0 in 2023, then jumped by 131.21% to $689000.0 in 2024, then declined by 18.14% to $564000.0 in 2025.
- Business Quant data shows INBX's Depreciation & Amortization (CF) at $564000.0 in Q4 2025, $582000.0 in Q3 2025, and $662000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | 523,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 523,000.00 |
| Dec 31, 2025 | 564,000.00 |
| Sep 30, 2025 | 582,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 675,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 304,000.00 |
| Jun 30, 2023 | 295,000.00 |